Navigation Links
Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
Date:5/7/2012

SAN DIEGO, May 7, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that Janet Roemer, Executive Vice President and Chief Operating Officer, will present at the upcoming Deutsche Bank Clean Tech, Utilities and Power Conference as part of the biofuels panel.  The panel is scheduled to begin at 2:15 p.m. ET on Monday, May 14, 2012 in New York City.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates, lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates, dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Sarah Carmody

Manager, Corporate Communications
858-431-8581

sarah.carmody@verenium.com


 

 


'/>"/>
SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verenium Announces 2010 Business Update and Outlook for 2011
2. Verenium Announces Changes in Senior Management
3. Verenium Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
4. Verenium Corporation to Announce First Quarter 2011 Financial Results
5. Verenium Reports Financial Results for the First Quarter Ended March 31, 2011
6. Verenium to Host Analyst and Investor Day
7. Verenium Launches Second Enzyme Product for Oilfield Services
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... -- Intec Pharma Ltd. (NASDAQ: ... announced the appointment of Pnina Strauss-Levy as ... Strauss-Levy has 15 years of experience in clinical research ... record, having supported the advancement of several products through ... the United States and ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... 2, 2016  Deerfield announced today it led ... Vision, Inc. Graybug Vision is an early stage ... transform care for ocular diseases including wet age-related ... was first developed at Johns Hopkins University and ... Graybug Vision is developing ophthalmology ...
Breaking Medicine Technology:
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Advanced Spine ... to help restore its patients’ health, is hosting a free seminar on stem cell ... be held at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, Ventura, CA. ...
(Date:5/4/2016)... ... 04, 2016 , ... Mediware Information Systems, Inc . ... that helps blood and marrow transplant (BMT) programs meet compliance and accreditation standards ... continued to enhance core application features. These enhancements are designed to help BMT ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... Scientific Group is scheduled on July 25-27, 2016 at Las Vegas. It aims ... care professionals from educational institutes and research organizations across the globe; making the ...
(Date:5/3/2016)... ... , ... The National Association of Professional Women (NAPW) honors ... Circle. She is recognized with this prestigious distinction for leadership in business. NAPW is ... and over 200 operating Local Chapters. , “I’m pleased to welcome Barbara into this ...
(Date:5/3/2016)... ... , ... Sue Desmond-Hellmann, chief executive officer of the Bill & Melinda Gates ... possibility in her keynote address at Georgia State University’s spring commencement on ... rich experience as a scientist, physician and executive, Desmond-Hellmann leads the Gates Foundation’s efforts ...
Breaking Medicine News(10 mins):